Addressing the challenges of phenotyping pediatric pulmonary vascular disease
- PMID: 28680562
- PMCID: PMC5448545
- DOI: 10.1086/689750
Addressing the challenges of phenotyping pediatric pulmonary vascular disease
Erratum in
-
Corrigendum.Pulm Circ. 2017 Apr-Jun;7(2):559. doi: 10.1177/2045893217706334. Pulm Circ. 2017. PMID: 28597768 Free PMC article. No abstract available.
Abstract
Pediatric pulmonary vascular disease (PVD) and pulmonary hypertension (PH) represent phenotypically and pathophysiologically diverse disease categories, contributing substantial morbidity and mortality to a complex array of pediatric conditions. Here, we review the multifactorial nature of pediatric PVD, with an emphasis on improved recognition, phenotyping, and endotyping strategies for pediatric PH. Novel tailored approaches to diagnosis and treatment in pediatric PVD, as well as the implications for long-term outcomes, are highlighted.
Keywords: childhood; long-term outcomes; pulmonary hypertension; registry studies.
Figures
References
-
- Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension. J Am Coll Cardiol 2013; 62: D117–126. - PubMed
-
- Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: Guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132: 2037–2099. - PubMed
-
- Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012; 125: 324–334. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
